Obesity : The Microbiome at the Intersection of Nutrition and Pharma

With more than one billion people living with obesity worldwide—and its economic burden projected to reach $4.32 trillion annually by 2035—obesity remains one of the most pressing global health challenges of the 21st century. While GLP-1–based pharmacotherapies dominate headlines, Seventure Partners—a pioneering venture capital firm specializing in health, nutrition, and microbiome innovation through its dedicated Health for Life Capital funds—is releasing a scientific report that synthesizes global advances in gut microbiome research in obesity and metabolic health, highlighting its potential to serve as a foundation for sustainable, personalized therapeutic strategies that complement and extend conventional drug-based treatments.

A Global Health and Economic Crisis

According to the World Health Organization, 2.5 billion adults were overweight in 2022, including 890 million living with obesity. The World Obesity Atlas 2025 reports that this number has now surpassed one billion. If current trends continue, the WHO projects that 60% of adults will be affected by 2050. The World Obesity Federation estimates that the economic impact of overweight and obesity—including healthcare costs, lost productivity, and premature mortality—will reach $4.32 trillion annually by 2035, equivalent to nearly 3% of global GDP, comparable to the economic impact of COVID-19 in 2020.   In this context, GLP-1 (glucagon-like peptide-1) agonists have been hailed as a major breakthrough. The global market for these treatments is expected to reach $105 billion by 2030. However, this therapeutic class, as promising as it may be, also presents certain limitations that the scientific community is documenting with increasing precision.

The Limitations of Exclusively Drug based Approaches

		The Seventure Partners report highlights several unmet needs with current GLP-1 treatments. Clinical studies reveal that fewer than 50% of patients continue their treatment beyond 12 weeks, raising the critical question of result durability. Weight loss effects remain contingent on continuous medication use.   Furthermore, these therapies profoundly alter the intestinal ecosystem. GLP-1 agonists change how food transits through the gut and its fermentation patterns, which can disrupt microbiome composition. Other documented effects include loss of muscle mass (not just fat mass), frequent gastrointestinal disorders, and nutritional deficiencies linked to reduced appetite.

	"These findings do not call into question the proven benefits of GLP-1s, but they underscore the need for complementary and supplementary approaches to ensure healthy and sustainable weight loss over the long term," the report states.

	The Microbiome: An Underutilized Physiological Lever

	This is precisely where the gut microbiome offers major opportunities. GLP-1 is not just a pharmaceutical molecule—it is a hormone naturally produced by L-cells in the intestine. And this production is directly modulated by the microbiome.   Recent scientific research demonstrates that gut microbiome metabolites—particularly short-chain fatty acids (SCFAs)—naturally stimulate GLP-1 secretion. In other words, a healthy microbiome can activate the same metabolic pathways as medications, through physiological mechanisms.   The Seventure Partners report thus identifies the microbiome as a cornerstone of holistic, sustainable therapeutic strategies guided by precision medicine. This approach does not aim to replace existing treatments but to complement them and optimize their long-term effectiveness.

	A Rapidly Maturing Market

	This convergence of microbiome and metabolism is opening a high-growth market segment. According to analyses by ResearchAndMarkets and Global Industry Analysts, the global microbiome therapeutics market is expected to grow from $1.4 billion in 2024 to $21.5 billion by 2030, representing annual growth of nearly 57%. The obesity segment shows one of the strongest dynamics with a CAGR of 56.8%, alongside opportunities in oncology, chronic and age-related diseases, and gut-brain axis applications (neurodegenerative diseases, mental health, etc.).   For comparison, the GLP-1 agonist market is expected to reach $105 billion by 2030 (Morgan Stanley). The 1-to-5 ratio between these two markets illustrates both the maturity of pharmacological approaches and the significant catch-up potential of microbiome-based solutions.   Europe shows annual growth of 35.4% in this segment (Grand View Research), driven notably by public-private partnerships and the European Commission's 2025 Biotechnology Roadmap, which prioritizes microbial therapeutics for health and sustainability.

	A Broad Range of Therapeutic Innovations

	Isabelle de Cremoux's analysis maps the various product categories under development in this field: fecal microbiota transplantation (FMT), Microbiome Restoration Therapy (MRT), live biotherapeutic products (LBPs), next-generation probiotics, prebiotics, postbiotics, and functional dietary fibers. These innovations follow distinct regulatory pathways and offer complementary mechanisms of action.   A key finding emerges from the report: the need for personalized approaches. The variability in individual responses to microbiome-based treatments requires consideration of each patient's baseline microbiome composition and functions. This heralds the advent of precision medicine applied to obesity.

	Research Priorities to Be Strengthened

	The report also identifies priority research areas to accelerate the clinical translation of these approaches: filling remaining mechanistic gaps, prioritizing randomized clinical trials in humans over animal experimentation, and standardizing methodologies for microbiome data collection and analysis.

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

First microbiome blood test developed

Zinzino has developed the Gut Health Test, completed with a simple finger prick. This innovative approach goes beyond the traditional stool testing, revealing not only which microbes are present but also whether they are active, what they produce, and how the body responds to them. The result is a deeper understanding of the gut-body connection and how diet and lifestyle influence it, and how to support a healthier, more resilient body from the inside out. 

 

“This test provides so much more information than the traditional gut microbiome test, but how the body processes tryptophan, an essential amino acid found in food, and how this affects gut and metabolic health,” says Dr. Martina Torrissen, Zinzino’s Research & Development Specialist. “By measuring these signals in the blood, we can give clear, science-based guidance on how to eat and how to live to support a healthier gut. It’s so important for wellness, since the gut is a powerful control center for the body, affecting metabolism, mood, immune system, and so much more.”

The Science 

 

Zinzino’s Gut Health Test is based on metabolomics, measuring the signals gut bacteria leave behind in the blood to gain insights into how the gut interacts with the body’s own processes in nutrient and energy metabolism. The markers measured (IPA, KYN, TRP, and their ratios) are widely studied in peer-reviewed science as indicators of microbial activity and immune-linked metabolism. All analyses are performed by Vitas AS, an independent chemical analysis laboratory and world leader in dried blood spot (DBS) testing.

Each personalised report provides detailed results that include customized recommendations with science-based guidance on diet and lifestyle to help improve and maintain results over time, as well as a follow-up test after 120 days to track the body’s response to diet and lifestyle adjustments.

Zinzino is leading the world toward a healthier future, empowering individuals to take charge of their personal well-being and long-term health with insights into their bodies at a cellular level and access to nutritional supplements scientifically proven to meet their specific needs.

 

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Oral microbiome

Image by Tim Sandle
 

There have been many advances with the human microbiome since the pioneering work led by the US National Institutes of Health began in 2007. One such area is the microbiome of the oral cavity.

Some interesting observations are around the variations of this microbiome of the mouth and how it is influenced by smoking and vaping/e-cigarettes. Both of these habits significantly alter the microbiome composition. In turn, this influences health and disease. Moreover, from a contamination control perspective, the activities impact the normal levels of control we might expect with a facemask, in terms of the types of organisms we might detect from general poor mask wearing (like elevated levels of Staphylococcus aureus), to a weakening of the mask due to factors like increased saliva viscosity.

This week’s article looks at new insights into the microbiome of the human mouth and weighs up what this means for contamination control… https://www.linkedin.com/pulse/open-wide-oral-microbiome-implications-smoking-health-professor-tim-ecvxe/

 

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)